Drug Trial Radar · NCT02321202
Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer
Last checked: Nov 20, 2026Latest source record: Aug 22, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
320
Actual
Start
Mar 2010
Primary completion
Sep 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The safety and efficacy of ω-3 fatty acid in patients with liver cancer followed hepatectomy is not known. This study provided evidences that ω-3 fatty acid-based parenteral nutrition improved postoperative recovery for cirrhotic patients with liver cancer underwent hepatectomy..
Conditions
- Liver Cancer
- Cirrhosis
Interventions
Omega-3 Fatty Acid-Based Parenteral NutritionDrug
Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
StructolipidDrug
Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an "All-In-One" manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- complications (blood test for liver and renal function, urine output, postoperative complications)Time frame: 14 days postoperatively
- hospital stay (time of hospital stay after surgery)Time frame: 14 days postoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hepatic Surgery Center of Tongji Hospital
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.